Market Intelligence, Clinical Progress, and High-Purity Reagents for Developmental and Epileptic Encephalopathies (DEEs) and Neurodevelopmental Disorders.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for GNAO1 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | GNAO1 WT & Disease Mutant (R209C, G203R, R243H) Recombinant Protein High purity (>95%), Endotoxin <1EU/µg, Sequence Verified |
View GNAO1 Products |
| Gene Delivery | GNAO1 Promise-ORF / Lentivirus Full-length ORF for stable neuronal cell line construction |
View GNAO1 Products |
| Benchmark Control | GNAO1 Reference Protein (Wild-Type) Recombinant standard for GTPase activity assays |
View GNAO1 Products |
| Validator | GNAO1 siRNA Set For knockdown verification and specificity controls |
View GNAO1 Products |
| Paralog Screening | GNAI1 (Gi alpha subunit) Counter-screening against Gi/o family members |
View GNAI1 Products |
| Pathway Contrast | GNAQ (Gq alpha subunit) Parallel pathway comparison for selectivity assays |
View GNAQ Products |
| Pathway Partner | RIC8A Recombinant Protein Guanine nucleotide exchange factor (GEF) essential for Gαo activation assays. >95% purity. |
View RIC8A Products |
| Downstream Effector | ADCY5 Cell Line / Protein Adenylyl cyclase 5 for cAMP modulation readouts in functional assays. |
View ADCY5 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Disease mutant stability (R209C, G203R, R243H) | High-purity WT and disease-mutant proteins expressed in HEK293, Sequence Verified by Mass Spec |
| GTP-binding displacement assays | Nucleotide-free protein preparation, Theoretical MW confirmed, Endotoxin <1EU/µg |
| Gi/o family selectivity screening | GNAI1, GNAI2, and GNAO1 paralog panel available for cross-reactivity analysis |
| Neuronal cellular functional validation | High-titer Lentivirus particles for stable overexpression in SH-SY5Y and primary neurons |
| Pathogenic variant screening | Rational design of clinical mutants (e.g., G203R, R209C) with strictly verified Theoretical MW |
| Off-target pathway noise | Validated siRNA included for precise target specificity and background knockdown checks |
Live GNAO1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic landscape for GNAO1-related disorders is transitioning from symptomatic management to precision genetic interventions. As the causative link between GNAO1 mutations (particularly R209C and G203R) and Developmental and Epileptic Encephalopathy 17 (DEE17) becomes firmly established, drug developers are prioritizing allosteric modulators and antisense strategies that can differentially target gain-of-function versus loss-of-function variants. The next wave of R&D focuses on blood-brain barrier penetrant small molecules and CNS-targeted delivery systems. High-fidelity biochemical reagents that recapitulate wild-type and mutant GTPase kinetics are now the critical bottleneck in target validation.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Ultragenyx, NGLytics | GNAO1 Encephalopathy, Movement Disorders | GTP-binding displacement assay (Need nucleotide-free mutant proteins) |
| Antisense Oligonucleotides (ASO) | Ionis Pharmaceuticals | DEE17 (Early Infantile Epileptic Encephalopathy) | Cellular rescue assay (Need Lentivirus for stable disease model construction) |
| Gene Therapy | Taysha Gene Therapies | Ultra-rare neurological | Expression level quantification (High-purity reference standards) |
| Biologics (Peptide) | Academic Consortiums | Chronic Pain (peripheral) | Protein-protein interaction with GPCRs (Need conformationally active GNAO1) |
Molecular Differentiation & Assay Strategy
1. Nucleotide-State Selectivity (GDP vs GTP)
GNAO1 pathogenic mechanisms often involve impaired GTPase activity (constitutive activation or inactivation). Small molecule modulators must distinguish between GDP-bound and GTP-bound states.
- Assay Strategy: Nucleotide-dependent SPR/BLI binding assays; mant-GTPγS fluorescence polarization for binding kinetics; Malachite Green phosphate release for GTPase hydrolysis rates.
2. Subfamily Selectivity (GNAO1 vs GNAI1/GNAZ)
GNAO1 shares >85% sequence homology with Gi/o family members. Non-selective modulators risk neuroendocrine toxicity.
- Assay Strategy: Paralog counter-screening panel using sequence-verified human GNAI1, GNAZ recombinant proteins for orthogonal activity screening.
3. GEF-Dependent Functional Reconstitution
Ric8A is a key guanine nucleotide exchange factor (GEF) for Gαo, regulating GDP/GTP exchange. In vitro GTPase assays must incorporate Ric8A to reflect intracellular signaling dynamics.
- Assay Strategy: RIC8A-assisted GTPγS exchange assays; BRET or Split-Luciferase systems to detect Gαo-Ric8A interaction.
4. Downstream Functional Readout Integrity
GNAO1 primarily signals by inhibiting adenylyl cyclase (AC), reducing intracellular cAMP. Drug validation must confirm cAMP level restoration in cells.
- Assay Strategy: GloSensor cAMP or HTRF cAMP dynamic detection; ADCY5 overexpression/knockdown systems to verify target-effector relationships.
5. Pathogenic Mutant Functional Validation
Different mutations have opposite biochemical consequences (some cause GTPase inactivation/constitutive activation, others protein instability). Lead compounds must be validated across multiple pathogenic mutants.
- Assay Strategy: Build a recombinant protein library covering at least 3–5 high-frequency mutations (R243Q, G203R, E246K, A217V, I120M) for unified GTP binding and hydrolysis kinetics comparison.
TarMart Solution
TarMart addresses the differentiated assay needs for GNAO1 with the following technical solutions:
- Mutant Protein Library: Human WT GNAO1 and high-frequency pathogenic mutant recombinant proteins, purity >95%, sequence verified, endotoxin <1 EU/μg. Suitable for mant-GTP binding and GTPase activity assays.
- Lentivirus Particles: Full-length ORF for stable cell line generation in neuronal models (SH-SY5Y, primary neurons).
- Paralog Panel: GNAI1, GNAI2, GNAO1 ortholog pairs (human/mouse/cynomolgus) for species cross-reactivity validation.
- RIC8A Recombinant Protein: For GEF-assisted GTPγS exchange experiments.
- ADCY5 Cell Line/Protein: For cAMP modulation readouts in functional assays.